vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and Commercial Bancgroup, Inc. (CBK). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $21.2M, roughly 1.1× Autolus Therapeutics plc). Commercial Bancgroup, Inc. runs the higher net margin — 41.3% vs -373.3%, a 414.6% gap on every dollar of revenue.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
AUTL vs CBK — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $23.1M |
| Net Profit | $-79.1M | $9.5M |
| Gross Margin | — | — |
| Operating Margin | -337.9% | — |
| Net Margin | -373.3% | 41.3% |
| Revenue YoY | — | — |
| Net Profit YoY | 3.6% | 9.7% |
| EPS (diluted) | $-0.30 | $0.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $23.1M | ||
| Q4 25 | — | $23.5M | ||
| Q3 25 | $21.2M | $22.8M | ||
| Q2 25 | $20.9M | — | ||
| Q1 25 | $9.0M | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $10.1M | — |
| Q1 26 | — | $9.5M | ||
| Q4 25 | — | $9.9M | ||
| Q3 25 | $-79.1M | $9.5M | ||
| Q2 25 | $-47.9M | — | ||
| Q1 25 | $-70.2M | — | ||
| Q3 24 | $-82.1M | — | ||
| Q2 24 | $-58.3M | — | ||
| Q1 24 | $-52.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -337.9% | 53.8% | ||
| Q2 25 | -292.6% | — | ||
| Q1 25 | -726.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -384.1% | — |
| Q1 26 | — | 41.3% | ||
| Q4 25 | — | 42.2% | ||
| Q3 25 | -373.3% | 41.4% | ||
| Q2 25 | -229.0% | — | ||
| Q1 25 | -781.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -522.1% | — |
| Q1 26 | — | $0.69 | ||
| Q4 25 | — | $0.72 | ||
| Q3 25 | $-0.30 | $0.77 | ||
| Q2 25 | $-0.18 | — | ||
| Q1 25 | $-0.26 | — | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.22 | — | ||
| Q1 24 | $-0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | — |
| Total DebtLower is stronger | — | $118.2M |
| Stockholders' EquityBook value | $265.5M | — |
| Total Assets | $661.9M | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $86.1M | $154.8M | ||
| Q2 25 | $123.8M | — | ||
| Q1 25 | $95.8M | — | ||
| Q3 24 | $657.1M | — | ||
| Q2 24 | $705.9M | — | ||
| Q1 24 | $758.5M | — |
| Q1 26 | — | $118.2M | ||
| Q4 25 | — | $166.8M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $265.5M | $245.2M | ||
| Q2 25 | $346.5M | — | ||
| Q1 25 | $371.1M | — | ||
| Q3 24 | $477.0M | — | ||
| Q2 24 | $527.8M | — | ||
| Q1 24 | $582.0M | — |
| Q1 26 | — | $2.3B | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | $661.9M | $2.2B | ||
| Q2 25 | $721.0M | — | ||
| Q1 25 | $746.3M | — | ||
| Q3 24 | $827.5M | — | ||
| Q2 24 | $853.6M | — | ||
| Q1 24 | $901.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | — |
| Free Cash FlowOCF − Capex | $-72.3M | — |
| FCF MarginFCF / Revenue | -341.2% | — |
| Capex IntensityCapex / Revenue | 20.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-67.9M | $28.0M | ||
| Q2 25 | $-72.8M | — | ||
| Q1 25 | $-75.6M | — | ||
| Q3 24 | $-76.7M | — | ||
| Q2 24 | $-51.1M | — | ||
| Q1 24 | $-40.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-72.3M | $26.5M | ||
| Q2 25 | $-80.1M | — | ||
| Q1 25 | $-83.8M | — | ||
| Q3 24 | $-86.3M | — | ||
| Q2 24 | $-51.9M | — | ||
| Q1 24 | $-41.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -341.2% | 115.8% | ||
| Q2 25 | -382.6% | — | ||
| Q1 25 | -933.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -406.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 20.8% | 6.7% | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 91.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AUTL
Segment breakdown not available.
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
